Intra-Cellular Therapies (ITCI) AI Stock Analysis

• Market Cap: $14.05B
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: 46.62%
• EPS Growth: 50.50%
• Country: US
• Employees: 860
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.72
• Shares Outstanding: 55,261,000
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -11.31
• Price to Book (P/B): 11.84
• Price to Sales (P/S): 20.56
• P/FCF Ratio: -191.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $130.83
• Price Target Upside: -0.79% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 63 Neutral
• Price Target: ―

Intra-Cellular Therapies' stock is buoyed by strong revenue growth and a robust acquisition by Johnson & Johnson. However, its continued unprofitability, negative cash flows, and a high valuation remain significant challenges. The technical indicators suggest potential caution due to overbought conditions.

Positive Factors

Financial Performance

Caplyta revenues of $199.2M were slightly above consensus, indicating better-than-expected financial performance.

Regulatory Approval

FDA acceptance of lumateprone's sNDA for adjunctive MDD is a key update influencing the stock positively.

Strategic Acquisition

The acquisition makes strategic sense as it appears to fit nicely within JNJ's existing neuro franchise.

Negative Factors

Pending Acquisition

Downgrading to HOLD on pending acquisition by JNJ.

Pipeline Uncertainty

Other ITCI pipeline products could be meaningful, but are earlier stage, making it difficult to ascribe value to them.

Stock Downgrade

Analyst is downgrading ITCI from Buy to HOLD as the stock is not trading on fundamentals.

Intra-Cellular Therapies Business Overview & Revenue Model

Company Description

Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on the development and commercialization of innovative treatments for neuropsychiatric and neurodegenerative disorders. The company's lead product, CAPLYTA (lumateperone), is an FDA-approved atypical antipsychotic for the treatment of schizophrenia in adults. ITCI is dedicated to enhancing the lives of patients by advancing a pipeline of novel drugs that target underlying causes in mental health disorders.

How the Company Makes Money

Intra-Cellular Therapies makes money primarily through the commercialization of its lead product, CAPLYTA, which generates revenue from sales to healthcare providers, hospitals, and pharmacies. The company may also receive milestone payments, royalties, or other forms of income from partnerships and collaborations in the pharmaceutical industry. Additionally, ITCI invests in ongoing research and development to expand its product offerings and address unmet needs in the treatment of mental health disorders, potentially leading to future revenue streams.

Intra-Cellular Therapies Financial Statement Overview

Summary

Intra-Cellular Therapies is experiencing impressive revenue growth. However, sustained losses and negative cash flows indicate that the company is still in a growth phase, relying on investor funding. The solid balance sheet with significant equity provides a buffer, but achieving profitability remains a key challenge.

Income Statement

Intra-Cellular Therapies has shown strong revenue growth, with a significant increase from $22.53 million in 2020 to $680.85 million in 2024. However, the company remains unprofitable with a negative net income and negative EBIT/EBITDA margins, indicating continued operational challenges.

Balance Sheet

The balance sheet of Intra-Cellular Therapies is relatively strong, with a low debt-to-equity ratio reflecting conservative leverage. Stockholders' equity has improved significantly, and cash reserves are robust, contributing to financial stability.

Cash Flow

Cash flow from operations remains negative, suggesting ongoing cash burn. Despite this, the company has managed free cash flow through significant financing activities, indicating reliance on external funding to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	680.85M	464.37M	249.13M	81.71M	22.53M
Gross Profit	623.89M	430.63M	228.69M	73.67M	20.64M
EBITDA	-116.72M	-158.85M	-262.97M	-285.15M	-230.70M
Net Income	-74.68M	-139.67M	-256.26M	-284.13M	-227.01M
Balance Sheet
Total Assets	1.37B	728.29M	754.78M	489.92M	717.31M
Cash, Cash Equivalents and Short-Term Investments	1.00B	497.94M	591.90M	412.33M	657.45M
Total Debt	16.98M	16.94M	20.04M	25.41M	29.14M
Total Liabilities	218.45M	136.87M	98.71M	72.03M	60.45M
Stockholders Equity	1.15B	591.42M	656.07M	417.89M	656.86M
Cash Flow
Free Cash Flow	-73.50M	-124.47M	-270.96M	-259.87M	-230.34M
Operating Cash Flow	-73.18M	-124.20M	-270.19M	-259.54M	-230.07M
Investing Cash Flow	-335.15M	105.54M	-128.37M	280.34M	-480.30M
Financing Cash Flow	567.51M	17.81M	455.16M	11.52M	664.18M

Intra-Cellular Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	77 Outperform	$12.44B	18.61	18.36%	0.64%	14.23%	-0.84%
NBIX	74 Outperform	$12.67B	43.88	12.43%	―	21.73%	-19.24%
SUPN	70 Outperform	$1.78B	29.04	6.32%	―	11.82%	―
ITCI	63 Neutral	$14.05B	―	-8.58%	―	46.62%	50.50%
Sector *	60 Neutral	HK$15.27B	5.80	-7.43%	4.22%	11.60%	-21.06%
TEVA	57 Neutral	$19.25B	―	-18.98%	―	3.38%	-175.90%
VTRS	54 Neutral	$10.77B	―	-21.25%	5.23%	-6.88%	-6809.78%

Intra-Cellular Therapies Corporate Events

Intra-Cellular Therapies Completes Merger with Johnson & Johnson

On April 2, 2025, Intra-Cellular Therapies notified the Nasdaq Stock Market of its merger completion and plans to delist its shares from the Nasdaq Global Select Market. This move is part of a broader change in control as the company becomes a wholly-owned subsidiary of Johnson & Johnson, with the merger valued at approximately $14.6 billion. Following the merger, all previous directors resigned, and the company’s certificate of incorporation and bylaws were amended to align with those of the acquiring entity.

Johnson & Johnson to Acquire Intra-Cellular Therapies

Johnson & Johnson has entered into an agreement to acquire Intra-Cellular Therapies for approximately $14.6 billion, enhancing its neuroscience portfolio with Intra-Cellular’s CAPLYTA® and promising pipeline. The acquisition positions Johnson & Johnson strategically for growth in the neuropsychiatric and neurodegenerative disorder markets, as CAPLYTA® has the potential to become a standard treatment for major depressive disorder if approved by the FDA.